To limit toxicity, Lanitis et al. designed a trans-signaling CAR with two different signaling domains (CD3ζ and CD28) located in two different CARs and one T cell to link with mesothelin and FRα in tumor cells. This evidence concerns the gene MSLN and neoplasm.